Largest reduction from baseline of proportion of T315I-mutated BCR-ABL
| Reduction of mutated clone, % . | Patients, n (%), N = 46 . | 95% CI . |
|---|---|---|
| 100 | 7 (15) | 8-34 |
| 75-99 | 1 (2) | 0.1-14 |
| 50-74 | 9 (20) | 11-40 |
| 25-49 | 8 (17) | 10-37 |
| 1-24 | 3 (7) | 2-21 |
| 0 | 10 (22) | 13-43 |
| Not assessable | 8 (17) | NA |
| Reduction of mutated clone, % . | Patients, n (%), N = 46 . | 95% CI . |
|---|---|---|
| 100 | 7 (15) | 8-34 |
| 75-99 | 1 (2) | 0.1-14 |
| 50-74 | 9 (20) | 11-40 |
| 25-49 | 8 (17) | 10-37 |
| 1-24 | 3 (7) | 2-21 |
| 0 | 10 (22) | 13-43 |
| Not assessable | 8 (17) | NA |
Data represent the best individual response assessment in patients who had available postbaseline assessments; 95% CIs calculated for binomial proportion of a level of response against all other levels of response.
CI indicates confidence interval; and NA, not assessable.